Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

252.82
-5.6350-2.18%
Volume:2.09M
Turnover:530.50M
Market Cap:609.11B
PE:29.28
High:257.80
Open:256.22
Low:251.95
Close:258.45
52wk High:281.07
52wk Low:184.66
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.60
T/O Rate:0.09%
Dividend:5.24
Dividend Rate:2.07%
EPS(TTM):8.64
EPS(LYR):11.03
ROE:25.74%
ROA:8.59%
PB:7.17
PE(LYR):22.91

Loading ...

Judge Rejects Pfizer, BioNTech, and Moderna Bid to Dismiss Monsanto mRNA Patent Lawsuit

Stock News
·
Sep 29

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Perrigo Co. PLC Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Sep 29

Estee Lauder Cos. Cl a Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 29

Lawyers in Alabama's TikTok Settlement Set to Earn $14 Million

Reuters
·
Sep 29

Johnson & Johnson (JNJ) Gets a Buy from Scotiabank

TIPRANKS
·
Sep 28

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)

TIPRANKS
·
Sep 27

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 26

Johnson & Johnson Says Tremfya Significantly Improves Axial Psoriatic Arthritis Symptoms in Phase 4 Study

MT Newswires Live
·
Sep 25

Johnson & Johnson says Tremfya met endpoints in Phase 4 STAR study

TIPRANKS
·
Sep 25

J&J - Star Study Shows Tremfya Safety Profile Consistent with Psa; no New Safety Signals

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary Endpoint for Basdai Score Improvement at Week 24

THOMSON REUTERS
·
Sep 25

J&J - Tremfya Meets Primary and Major Secondary Endpoints in Axial Psa Study

THOMSON REUTERS
·
Sep 25

Johnson & Johnson Announces Tremfya® (Guselkumab) is the First and Only Il-23 Inhibitor to Show Significant Improvement in Spinal Pain and Stiffness in Landmark Axial Psoriatic Arthritis (Psa) Study

THOMSON REUTERS
·
Sep 25

Single Infusion of Carvykti Delivered Five-Year Treatment-Free Remissions in 50% of Patients in Early Line Relapsed/Refractory Multiple Myeloma

Reuters
·
Sep 25

J&J - Carvykti Delivers Five-Year Treatment-Free Remissions in 50% of Early Line Rrmm Patients

THOMSON REUTERS
·
Sep 25

J&J - Five-Year Overall Survival Rate 69.2%, Median Progression-Free Survival 60.5 Months

THOMSON REUTERS
·
Sep 25

Estee Lauder Cos. Cl a Stock Underperforms Thursday When Compared to Competitors

Dow Jones
·
Sep 25

Nanobiotix advances cancer nanotherapeutics and bolsters cash runway into 2029

TIPRANKS
·
Sep 25

France's Nanobiotix H1 Net Loss Widens on Lower Revenue, Absence of 2025 One-Off Gain

Reuters
·
Sep 25